1. How will you prescribe lipase, protease, and amylase Patients with cystic fibro-
components? sis are often prescribed en-
zyme replacement for pan-
creatic secretions each re-
placement drug has amy-
lase, lipase and protease
components, however the
drug is prescribed in units
of lipase
2. What is the medication of choice for hypertensive cri- Surgical resection of the
sis with pheochromocytoma? tumor is the first treat-
ment of choice either my
open laparotomy or la-
paroscopy either surgi-
cal option requires pri-
or treatment of nonspe-
cific irreversible adrener-
gic adraonoreceptor block-
er phenoxybenzamine or a
shorter acting alpha antag-
onists, prazosin, terazosin,
and doxazosin. Mainly use
phenozibenamine in prac-
tice. Doing so promotes the
surgery to proceed while
minimizing the likelihood
of severe intraoperative hy-
pertension which is likely
when the tumor is manipu-
lated.
,3. What is the onset of action, peak of action, and dura- (Intermediate Acting) NPH
tion of action of each insulin preparation? Onset-60-90 min after ad-
ministration,
Peak 48 hrs
Duration 10-18 hrs.
(Short Acting) Regular On-
set 30-60 min
Peak 2-4 hrs
Duration 6-10 hrs
(Long Acting) Aspart,
Lispro, Glulisine
Onset less than 15 min
Peak 1-2 hrs
Duration 3-6 hrs
(Long Acting) Glargine, De-
temir
Onset 1-2 hrs
Peak NO PEAK
Duration 24 hrs
4. Identify the symptoms of hypoglycemia, hyper- Hypoglycemia- dizziness,
glycemia, and ketoacidosis. confusion, diaphoresis,
tachycardia
Hyperglycemia- polypha-
gia, polydipsia, polyuria,
blurred vision, and fatigue
Ketoacidosis- hallmark
symptoms include acetone
breath like nail polish re-
, mover or fruity breath. Also
abdominal pain, nausea,
vomiting and sob.
5. When changing from NPH to glargine insulin, how will The initial dose of glargine
you adjust the patient's dose? is reduced by 20% to pre-
vent hypoglycemia.
6. How does metformin work? Decreases hyperglycemia
by decreasing hepatic glu-
cose production called he-
patic gluconeogenesis. The
average person with type
2 diabetes has three times
the rate of gluconeogen-
esis, metformin treatment
reduces this by over 1/3rd.
The molecular mechanism
of metformin isn't com-
pletely understood. In ad-
dition to suppressing he-
patic glucose production,
metformin increases insulin
sensitivity, enhances pe-
ripheral glucose uptake by
inducing the phosphoriliza-
tion of glu4 enhancer fac-
tor, decreases insulin in-
duced suppression of fat-
ty acid oxidation, and de-
creases absorption of glu-
cose from the GI tract.